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Abstract
Objective: Public health research is an endeavour that often involves multiple relationships, far-reaching
collaborations, divergent expectations and various outcomes. Using the Tall Girls Study as a case study, this paper
will present and discuss a number of methodological, ethical and legal challenges that have implications for other
public health research.
Approach: The Tall Girls Study was the first study to examine the long-term health and psychosocial effects of
oestrogen treatment for tall stature.
Results: In undertaking this study the research team overcame many hurdles: in maintaining collaboration with
treating clinicians and with the women they had treated as girls - groups with opposing points of view and
different expectations; using private practice medical records to trace women who had been patients up to forty
years earlier; and exploring potential legal issues arising from the collection of data related to treatment.
Conclusion: While faced with complex challenges, the Tall Girls Study demonstrated that forward planning,
ongoing dialogue between all stakeholders, transparency of processes, and the strict adherence to group-
developed protocols were keys to maintaining rigour while undertaking pragmatic research.
Implications: Public health research often occurs within political and social contexts that need to be considered in
the planning and conduct of studies. The quality and acceptability of research findings is enhanced when
stakeholders are engaged in all aspects of the research process.
Introduction
Public health research often involves investigation of
topics that are broad and complex and generates find-
ings with social as well as health implications. This
paper tells the story of the Tall Girls Study and uses it
as a case study to consider issues that may arise in
other public health research. The paper begins with the
background to the Tall Girls Study. It then discusses
aspects of study design, particularly in regard to acces-
sing an appropriate cohort, tracing study participants
and practicalities of data collection. Ethical issues and
consumer participation are also discussed.
The first long-term follow-up of girls treated with oes-
trogens, the Tall Girls Study, was undertaken in Austra-
lia between 2000 and 2003 [1]. The study examined a
broad range of health and psychosocial outcomes in
women treated with high dose oestrogens as adolescents
in an attempt to reduce their adult height and compared
them with women who were assessed but not treated for
tall stature. While the short-term side-effects of this
treatment, including weight gain, menstrual irregulari-
ties, nausea, night cramps and limb pains, benign breast
disease, excessive vaginal discharge, thrombosis and
ovarian cysts were well documented [2-5], nothing was
known about the long-term health and psychosocial out-
c o m e so ft h i st r e a t m e n t .T he study contributed to a
broader understanding of the associations of high levels
of oestrogen in adolescence on reproductive [1] and
other outcomes [6-9].
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Very little information is available on the evolution of
the use of high dose oestrogens as a treatment for tall
stature in healthy adolescents. After the successful use
of this treatment in children with pituitary gigantism in
the 1940s [10], clinicians in the United States (US)
extended the treatment to tall girls with concerns about
their height but who had no associated pathology [3].
The first report of treatment of tall girls was published
in 1956 [11]. There have been no randomised controlled
trials of treatment effectiveness, and cohort studies have
demonstrated that treatment is only moderately effective
[9]. Despite this, the treatment became an accepted clin-
ical practice in many countries including Australia
[12,13].
Treatment was based on the knowledge that normally
in puberty oestrogen inhibits further increases in height
by fusing the epiphyses (growth-plates) of the long
bones. Most treating clinicians considered treatment
acceptable if a girl’s adult height was predicted to be
above the 97
th percentile or two standard deviations
above the mean female adult height in the given popula-
tion [2,4]. Determination of predicted adult height
involved estimating bone age after an x-ray of the hand
and wrist and assessing the remaining growth potential
[14-16]. The various methods for calculating predicted
adult height are prone to error [17].
The earliest predicted height criterion for oestrogen
treatment in the US was 173cm in 1956 [11,18,19] and
this gradually increased over time but continued to fluc-
tuate between countries. During the 1970s, Australian
girls with a predicted adult height of ≥177cm were eligi-
ble for treatment [2]; in the US, girls whose predicted
adult height was above 173cm [20] or 182.9cm [21]
were also treated; and in Germany and the Netherlands
the treatment criterion was a predicted height of
≥180cm [22,23]. Age at initiation and duration of treat-
ment also varied considerably and was strongly asso-
ciated with overall treatment effectiveness. The clinical
challenge was that the accuracy of predicting adult
height increased after the age of ten years (or closer to
puberty) however the potential height reduction dimin-
ished [24]. Some clinicians waited until girls grew to an
arbitrary height before initiating treatment: 167cm in
Australia [2]; 169.5cm in the US [24]; and 170cm in
Europe [25]; while others waited until girls reached pub-
erty when they were more likely to be psychologically
ready for the effects of treatment on their development
but when treatment may be less effective [26]. Duration
of treatment varied but was generally two to four years
[2,23,27]. Treatment regimes varied considerably and
initially were a combination of oestrogen and testoster-
one [11]. Various preparations of oral synthetic [2,23,28]
or conjugated oestrogens [25] were given continuously
or cyclically; oestrogen pellets were inserted under the
skin at six monthly intervals [29] for some; and intra-
muscular injections of oestrogen were given to others
[24,26,30,31].
The rationale for treatment was to reduce perceived
psychosocial ‘risks’ tall girls may face in adulthood.
These included physical deformity, through tall girls’
adoption of slouching in an effort to reduce their height;
and psychological distress and social withdrawal as a
consequence of tall girls’ difficulty conforming to cul-
tural stereotypes [2,3,18,24,32,33]. However, there was
very little reporting of any evidence for these assump-
tions [13] and there are very few published studies
reporting psychosocial outcomes following treatment.
Three relevant studies [33-35] were limited by small
sample sizes, the participants being still relatively young,
and the fact that the investigators were treating clini-
cians which may have affected responses. While treat-
ment is relatively uncommon now in Australia, it was
still being used in the US in 2002 [36]; is currently
recommended for the management of familial tall sta-
ture [37]; and more controversially has been proposed
as a form of clinical management of disabled children to
reduce their height and increase manageability [38].
The use of synthetic oestrogens as a medical treat-
ment to reduce the height of tall girls was relatively
unknown among the general public during the decades
it was at its peak in Australia and elsewhere. Even
within some families a girl’s height assessment and
treatment was kept a secret from other family members.
Public awareness of the treatment of tall girls came
about in Australia in 1997, when the treatment became
part of a wider debate in the Australian Federal Parlia-
ment on the use of human biological products and post-
war medical experimentation [39]. Subsequent to the
media coverage of this issue, the need for a comprehen-
sive follow-up study was raised independently both by
Australian endocrinologists and by women who had
been assessed and treated for tall stature as adolescents.
These women formed a lobby group, Tall Girls Inc., to
petition the government for a follow-up study citing a
range of health concerns and that their families had
been unaware of the experimental nature of this treat-
ment [40].
Clinicians and Tall Girls Inc. alike had concerns about
the possibility of long-term effects of oestrogen treat-
ment, particularly exposure to diethylstilboestrol (DES),
which is associated with serious adverse outcomes when
given to pregnant women [41,42].
In early 1998, the paediatric endocrinology group at
the Royal Children’s Hospital was under increasing pres-
sure to conduct a follow-up study to examine long-term
outcomes of treatment and was looking for a group of
researchers with whom to collaborate. Researchers at La
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and had significant experience in conducting long-term
follow-up studies in women’s health met with treating
clinicians. Following an agreement for the need for a
study and for formal collaboration, a period of intense
discussion and consultation was undertaken with all
parties to formulate the study design and research ques-
tions. Given their investment in the project and the
sense of disenfranchisement that many treated tall girls
felt from the original decision-making, Tall Girls Inc.
and particularly the president, Janet Cregan-Wood, were
involved from inception in the study design process. In
2000, the National Health and Medical Research Coun-
cil (NHMRC) provided funding for the study (known as
the Tall Girls Study).
Study design
The study was, by necessity, designed as a retrospective
cohort study. Ideally, the cohort would be comprised of
all Australian women assessed for tall stature. However,
the number of women who were assessed and/or treated
in Australia was not known. What was known was that
the private practice of one paediatric endocrinologist
comprised a high proportion of treated tall girls. Meti-
culous records had been kept and the specialist was will-
ing to make them available for the study. In addition, a
large number of women had been assessed for treatment
as adolescents but their estimated adult height did not
warrant treatment or their parents elected not to have
the treatment. All treated and untreated (assessed only)
women were considered eligible to participate and the
i n c l u s i o no fu n t r e a t e dw o m e np r o v i d e da ni m p o r t a n t
comparison group of tall women who had been through
similar referral pathways.
To ensure the most complete coverage possible, a
number of direct and indirect strategies were used to
maximise recruitment. These included having access to
the private medical records of the main treating clini-
cian so we could trace women through public records
and invite them to participate in the study; having
access to the mailing list of Tall Girls Inc. so we could
invite women directly; advertising the study through the
mailing list of a tall women’s clothing company; inviting
other paediatric endocrinologists who may have treated
tall girls to participate; and advertising through profes-
sional medical, nursing and ancillary associations. Some
tall girls were referred for a height assessment by doc-
tors and nurses undertaking yearly health checks in pri-
vate girls’ schools and so information about the study
was placed in alumni newsletters of these schools.
While these strategies increased the opportunity for
women to self-refer into the study, reliance on self-refer-
ral as the only recruitment method would have resulted
in a study sample that was too small and findings prone
to selection bias [43] if volunteers over-represented
women reporting adverse outcomes.
A cohort of 1,432 eligible subjects was identified:
1,248 from medical records (1,222 of these from one
paediatric endocrinologist) and 184 from self-referrals.
572 women in the cohort were treated and 860 women
were untreated. A total of 1243 (90% of treated and 84%
of untreated) were traced and invited to participate in
the study: of these, 398 treated and 448 untreated
women agreed and completed a postal questionnaire.
Women were also invited to complete a computer
assisted telephone interview (CATI) which collected
information on reproductive history and a measure of
mental health measure; 371 treated women (72% of
those traced) and 409 (56%) untreated women com-
pleted this. Written consent to abstract data from medi-
cal records was provided by 93% (n=726) of women
who completed the interview. However, medical records
were available for only 618 (75% of treated and 95% of
untreated).
The mean age of participants was 39·8 years (range
20-55) in the treated group and 37·7 years (range 23-54)
in the untreated group. Treated and untreated partici-
pants were similar in their marital status and highest
level of education achieved. Self-reported current height
was greater in treated women (mean 179·0cm, SD
4·0cm) than in untreated women (mean 176·8cm, SD
4·9cm). Similarly, the first recorded estimated mature
height was greater in the treated women (mean
181·5cm, SD 6·3cm) than in the untreated (mean
174·3cm, SD 4·6cm).
The issues that we encountered in assembling a
cohort were very similar (on a smaller scale) to those
encountered by researchers aiming to investigate the
health outcomes for women and their offspring who
were administered diethylstilbestrol (DES) during preg-
nancy or were exposed in-utero [44], in that it was
impossible to enumerate the total exposed cohort,
accessing medical records posed a number of challenges
and it was difficult to trace women over a long period
of time.
Clinical collaboration
In Australia, the medical records of private medical
practitioners are the property of the medical practi-
tioner, not the individual to whom the record refers.
Under both the Privacy Act 1988 (Commonwealth) and
the Health Records Act 2001 (Victoria), records cannot
be divulged to a third party without the individual’s con-
sent, although there are some exemptions, one of which
is where the research is in the public interest. It is a
well accepted practice that health providers will contact
patients on behalf of researchers to invite them to parti-
cipate in relevant research. If the individual agrees,
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and the research team. In Australia, private practitioners
are not obliged to keep records of children once they
reach 25 years of age or seven years after last contact.
This provision protects privacy and trust in the doc-
tor-patient relationship however, it also opens the possi-
bility of gate-keeping by clinicians. This issue requires
further ethical consideration as a clinician may decide
the research is not appropriate, or that the patient
would not be interested or that participation would not
be in the patient’s best interests, thus removing choice
from the individual.
These provisions have implications for investigating
and reporting the long-term safety and outcomes of
treatment. In the Tall Girls Study, we ascertained
through Tall Girls Inc and the Australian Endocrinology
Society that at least 51 other Australian doctors pro-
vided treatment. The research team traced and sought
assistance from 35 doctors (16 were either in nursing
homes or deceased) to determine whether they had trea-
ted tall girls, still had the girls’ medical records and
would be willing to recruit these women to the Tall
Girls Study. Thirty-two doctors responded to the
request: seven were willing to assist and could identify
up to 100 eligible women; eight doctors had retained
their medical records but could not readily identify
those of tall girls; 12 doctors treated women but their
records had been destroyed or were no longer in their
possession; two doctors were unwilling to recruit
women; and three had no recollection of having treated
or assessed girls. Researchers investigating outcomes fol-
lowing use of DES faced similar challenges, with records
destroyed, ineligible records or physicians being unwill-
ing to participate [44].
I nt h ec a s eo ft h eT a l lG i r l ss t u d y ,a g r e e m e n tw a s
made between the private medical practitioners and the
research team that the medical practitioners would
release a small amount of information to researchers for
tracing purposes (with no medical or treatment details)
with appropriate human ethics committee approval.
Once a current address was obtained, the medical prac-
titioner would contact women on the researchers’
behalf. During the tracing phase of the study, the specia-
list with the largest number of records died, however his
family, in-line with his wishes, allowed the project to
continue. Ethical approval was obtained for a modifica-
tion to the approach in that the letter was sent by the
researchers outlining how the woman’s details had been
obtained. While this meant that we were directly con-
tacting the majority of women (a small number of
whom were uncomfortable about this), it also had bene-
fits. Some women were angry about their treatment and
may not have responded to an approach directly from
their doctor. The research team took particular care to
emphasise that while collaborating with, and in contact
with both clinicians and Tall Girls Inc., the research was
conducted by an independent research team. In all
cases, women were initially contacted by mail using a
standardised letter. The opening paragraph incorporated
minor modifications according to whether the research
team was conducting the woman directly, as a result of
a self-referral to the study, the research team were
directly conducting women who were former patients of
the deceased practitioner or a clinician was sending the
letter to a former patient on behalf of the research team.
Tracing and recruitment
One of the greatest challenges the study faced was tra-
cing women between 14 and 40 years after they were
assessed or treated for tall stature. Much of the informa-
tion from medical records was out of date, as parents
were unlikely to still be living at the same address and
most women would have changed their surname with
marriage. Despite assistance from the Australian Elec-
toral Commission (AEC), who performed record linkage
on name and date of birth, tracing women using the
medical record data to try and link names and addresses
over time involved tedious and time-consuming trawling
through years of public records including electoral rolls,
telephone books and death notices, all on microfiche.
The National Death Index (NDI) was also used to
record link registered Australian deaths with the names
and dates of birth of women. Tracing and contacting
women to invite them into the study was crucial to help
minimise selection bias and to build confidence in the
study findings. Considerable effort was made in locating
women who may have changed their name.
Once again, this experience had many parallels with
the experience and strategies used in the Diethylstilbes-
trol-Adenosis (DESAD) project conducted by Nash and
colleagues [44]. The Tall Girls Study traced 87% of
women identified as eligible from medical records [1], a
great result given the limited information available and
the duration of time to follow-up and similar to that
traced by Nash et al (1983) [44]. The effectiveness of
different strategies will vary greatly between countries; it
is important to tailor strategies according to local cir-
cumstances to obtain optimal results. For instance, in
Australia, voting is compulsory so use of the electoral
roll provides good population coverage, where voting is
not compulsory this will not be the case.
In some instances, following detailed tracing, research-
ers were still hesitant about the accuracy of the match.
In order to safeguard privacy, and due to the sensitivity
of the topic, ethics approval was obtained to send a very
generic letter (with no information regarding the
research topic) verifying the accuracy of the match.
Once the match was verified, the initial recruitment
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located for the parents but not the child. In this case we
contacted the parents and asked them for contact details
of their daughter(s) or requested that they forward to
them our letter of invitation. Some parents were reticent
or refused to do this as they felt it would raise issues
they would rather let lie. In these instances we tried to
collect limited data from the parents on their daughter’s
health and relationship status.
In all instances it is vital for rigorous epidemiological
research that access to sources for tracing be main-
tained. Privacy is important; however this must be
balanced with the public expectation that information is
available on the long-term impact and effects of medical
treatments. Studies would be unable to be conducted, or
the validity of which would be compromised, if access
to named or identifying data on a population-based
level was not possible.
The issues outlined in the previous two sections,
namely storage and retrieval of medical records, avail-
ability of records and willingness of practitioners to par-
ticipate, tracing and recruitment of participants, have
ongoing implications for public health research. Each
year new treatments and new medications are added to
standard clinical practice, the long-term implications of
which cannot always be foreseen [44]. An interesting
example, with some parallels to the treatment of tall
girls, is the current use of hormone treatments for short
stature [45]. Another example is the potential need to
trace women administered human pituitary growth hor-
mone (hGH) [46] and human pituitary gonadotrophin
[47]. Tracing plays an important part in accurately
reporting outcomes and reducing bias in findings. It
requires access to population-based identifying data
sources or use of a unique identifying number. However,
prior to this, accurate records of treatment must be
kept.
Practicalities of data collection
The Tall Girls Study collected data on multiple health
and psychosocial outcomes. This necessitated a range of
quantitative and qualitative methods each of which had
specific challenges. The primary exposure of interest
was the synthetic oestrogens used to accelerate puberty
a n dr e t a r dg r o w t h( h e i g h t )w h i c hw o u l db ea s c e r t a i n e d
through access to medical record data. A postal ques-
tionnaire collected self-reported information on current
health status using standard validated tools, treatment
history, family attitudes to tall stature, perceived advan-
tages and disadvantages to tall stature and satisfaction
with treatment using structured and open-ended ques-
tions; and personal and demographic details including
current height. Information considered more complex
or sensitive including reproductive and sexual history
and mental health status was collected using a computer
assisted telephone interview (CATI). While the majority
of women participated in all components of the study, a
small number of women chose to only participate in a
component of the study. Postal questionnaires were
mailed to women with the initial approach letter outlin-
ing the study. Return of a completed questionnaire
implied informed consent. Included with the postal
questionnaire were two separate consent forms, one for
permission to access their medical record for assessment
and treatment details, and the second for permission to
be contacted for a CATI interview.
Due to the number of telephone interviews that
needed to be conducted over a relatively short period of
time and the difficulties in staffing and scheduling these,
it was decided to contract these interviews to a com-
mercial interviewing company. Once interviewing com-
menced it became clear that the interviewers had very
little experience in health, they did not tailor contact to
the times that women had already indicated were conve-
nient and although initially they had indicated that they
were happy for the project manager to be on site and
monitor some of the interviews, in practice this was not
the case. The interviews weres i g n i f i c a n t l ym o r ec o m -
plex and took significantly longer than they had esti-
mated in their costing (despite a number of briefings).
The commercial company was not willing to address
these issues and only completed half of the CATI
interviews.
The remaining interviews were conducted in-house by
the project manager and two members of the project
team. This change meant that any queries about the
study or associated issues regarding being an assessed or
treated tall girl could be clearly and accurately
addressed. An additional advantage of the project team
being involved in data collection was that it gave a good
sense of the strengths and weaknesses of data items
which then informed the analysis process. While con-
ducting the interviews in-house had advantages, it also
had costs (both economic and emotional). A small num-
ber of CATIs needed to be conducted with women who
were living overseas and it required rescheduling of staff
work hours as a high proportion of interviews needed to
be conducted between 5 and 9pm at night and in some
instances in the early hours of the morning. Some of
these interviews were also emotionally taxing and the
three in-house interviewers conducted between 50-100
interviews each over the space of a few months. Regular
debriefing was required; this was conducted by other
team members.
Analysis of one of the primary outcomes, fertility, col-
lected by the CATI did not find any significant differ-
ence in rates of reporting between the interviews
conducted in-house or outsourced, which was reassuring
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outcome depression, with higher rates found by the in-
house interviewers and one interviewer in particular.
Depression was collected using a standardised instru-
ment, the CIDI. It is not possible to determine how
much the differences were in the result of how the
instrument was administered as opposed to differences
in the characteristics of the women interviewed. More
importantly, conducting the interviews in-house had
some less quantifiable benefits. For some participants
the interview was the first time they had discussed their
experience of assessment or treatment with anybody
and even though this wasn’t part of the CATI wanted to
share this as well as sometimes seeking information
about why certain examinations/tests were done. In-
house interviewers were able to listen (without commer-
cially driven time constraints) and appropriately respond
to their stories or requests for information. This may
also have broader long-term effects by providing women
with a positive experience of participating in research,
perhaps making them more likely to participate in other
studies in the future.
This experience illustrates the need for experienced
research staff to conduct interviews that are of a sensi-
tive and complex nature. This is important both for
ensuring the quality and accuracy of the data collected
but also in terms of providing a positive experience of
research for participants. The need for staff training and
debriefing should not be overlooked.
Ethical issues
The use of information from private medical records
without individual consent for the purposes of research
raises important legal and ethics issues [43,48]. As has
already been mentioned the study required access to
medical records held by private medical practitioners.
The research team needed to balance obtaining data on
long-term outcomes with not harming participants. For
some women, the study brought back difficult memories
and raised a topic that had previously been taboo within
the family. The research team put together detailed pro-
tocols regarding these issues. A small number of women
(less than five) were concerned about how their details
were obtained and these were immediately reported to
the ethics committee and were successfully resolved.
A more contentious issue was access to medical
records. Some women had been trying unsuccessfully to
access their medical record via the private practitioner
and there was previous (and current at the time the
study began) legal action between a small number of
women and one medical practitioner. At the beginning
of the study the research team investigated whether
study data could be subpoenaed in litigation or whether
data collected for the study could be accessed via a
Freedom of Information request. Examination of Victor-
ian freedom of information legislation suggested that it
may be possible but legal advice indicated that a request
for an exemption could be made given that such a pre-
cedent may jeopardise research more generally.
The knowledge that we were able to access the records
for research purposes prompted some women to ask us to
provide them with the information. Many women could
not remember what treatment they had received and were
eager to know. This placed the research team in an unu-
sual and difficult position: we had obligations to the medi-
cal practitioners who were assisting us with our research,
and to study participants [43]. After discussion with repre-
sentatives of the primary medical practitioner concerned,
and after legal advice and in line with the health privacy
principles of the Victorian Health Records Act (2001), we
developed a policy where women could be provided with a
summary of the data that was abstracted from the medical
record and also a summary of the data collected using the
study instruments. If the woman wanted to see the medi-
cal record or obtain copies of photos or other original
material she needed to contact the representative of the
relevant medical practitioner. In practice, less than 10
women requested access to their study records.
Consumer collaboration
The involvement of Tall Girls Inc. was crucial for a
number of reasons. One reason why the study was being
conducted was to address their concerns about the pos-
sible adverse outcomes of treatment. Their support of
the study was vital in terms of encouraging women to
participate and promoting the study through their net-
works and the media. The topic was particularly emotive
for this group of women. However, as any one study is
unable to answer all research questions, the research
team felt the participation of Tall Girls Inc. in the
research design process from the beginning to be impor-
tant. This involved numerous and lengthy discussions
about what the project could and could not do, as well
as their input into study questions. While time-consum-
ing, we believe that this investment of time and genuine
involvement in the research process had dividends for
both the research team and members of Tall Girls Inc.
It ensured that the study questions were relevant. At the
end of the study the group had more realistic expecta-
tions about the findings and accepted them more read-
ily. Some members of Tall Girls Inc reported to the
research team that they found their involvement in the
process to be empowering. While consumers and clini-
cians were involved in the development of the study
methodology and data collection instruments, the study
was conducted independently of both stakeholder
groups. Public health investigation intersects frequently
with the community and community advocacy groups; a
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Very few cancer clusters are found to be attributable to
a particular cause or exposure but frequently the find-
ings are received with scepticism. The experience of
active engagement and explanation of research process
and design may assist in this understanding.
Implications
This paper has provided the social and historical context
of a retrospective cohort study. Our experience with
undertaking this study has implications for wider public
health research. We believe active engagement with stake-
holders provided a positive experience of the research pro-
cess, improved the design of the study instruments and
facilitated acceptance and understanding of the study find-
ings. It also highlights the need for accurate record-keep-
ing and systematic storage of records over an extended
period of time and for access to records that allow tracing
to take place. Further clarification of ethical and legal
access to records would facilitate studies investigating
long-term outcomes of interventions and treatments.
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